A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy

[1]  Chen Zhao,et al.  Manipulating Offense and Defense Signaling to Fight Cold Tumors with Carrier‐Free Nanoassembly of Fluorinated Prodrug and siRNA , 2022, Advanced materials.

[2]  J. Lai,et al.  PAMAM Dendritic Nanoparticle-Incorporated Hydrogel to Enhance the Immunogenic Cell Death and Immune Response of Immunochemotherapy. , 2022, ACS Biomaterials Science & Engineering.

[3]  Yan Yang,et al.  Dual Closed-Loop of Catalyzed Lactate Depletion and Immune Response to Potentiate Photothermal Immunotherapy. , 2022, ACS applied materials & interfaces.

[4]  Jiulong Zhang,et al.  Watson-Crick Base Pairing-Inspired Laser/GSH Activatable miRNA-Coordination Polymer Nanoplexes for Combined Cancer Chemo-Immuno-Photothermal Therapy. , 2022, ACS applied materials & interfaces.

[5]  L. Bullinger,et al.  Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade , 2022, Oncoimmunology.

[6]  A. Yoon,et al.  Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses , 2022, Cancer Gene Therapy.

[7]  M. Coffey,et al.  Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice , 2022, Science Translational Medicine.

[8]  Takafumi N. Yamaguchi,et al.  Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy , 2022, Nature Communications.

[9]  P. Karoyan,et al.  PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells , 2022, Oncoimmunology.

[10]  Lingyan Lv,et al.  In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Xuesi Chen,et al.  Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity. , 2022, Biomaterials.

[12]  S. Workenhe,et al.  A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner , 2022, International journal of molecular sciences.

[13]  Saran Long,et al.  ER-Targeting Cyanine Dye as an NIR Photoinducer to Efficiently Trigger Photoimmunogenic Cancer Cell Death. , 2022, Journal of the American Chemical Society.

[14]  Liuxin Yang,et al.  Melittin-Based Nano-Delivery Systems for Cancer Therapy , 2022, Biomolecules.

[15]  Y. Chen,et al.  Stable Loading and Delivery of Melittin with Lipid-Coated Polymeric Nanoparticles for Effective Tumor Therapy with Negligible Systemic Toxicity. , 2021, ACS applied materials & interfaces.

[16]  Wei-Zen Sun,et al.  Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs. , 2021, Cancer letters.

[17]  K. Klingel,et al.  Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H , 2021, Viruses.

[18]  Zhiwei Xu,et al.  Sequentially pH-Responsive Drug-Delivery Nanosystem for Tumor Immunogenic Cell Death and Cooperating with Immune Checkpoint Blockade for Efficient Cancer Chemoimmunotherapy. , 2021, ACS applied materials & interfaces.

[19]  Xueyan Cao,et al.  Bottlebrush Polymer-Conjugated Melittin Exhibits Enhanced Antitumor Activity and Better Safety Profile. , 2021, ACS applied materials & interfaces.

[20]  Honglin Luo,et al.  Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges , 2021, Viruses.

[21]  Ming-zhu Jin,et al.  Immunogenic Cell Death-Based Cancer Vaccines , 2021, Frontiers in Immunology.

[22]  Jingwen Liu,et al.  Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[23]  H. Fechner,et al.  Coxsackievirus B3—Its Potential as an Oncolytic Virus , 2021, Viruses.

[24]  Juan Li,et al.  Fullerenols boosting the therapeutic effect of anti-CD47 antibody to trigger robust anti-tumor immunity by inducing calreticulin exposure , 2021 .

[25]  D. Mahoney,et al.  Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis , 2021, Journal for ImmunoTherapy of Cancer.

[26]  M. Solimena,et al.  miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas. , 2021, Human gene therapy.

[27]  Y. Soda,et al.  Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3 , 2021, Anticancer Research.

[28]  Bernardo A. Mainou,et al.  Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer , 2020, Molecular therapy oncolytics.

[29]  P. Marchetti,et al.  Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions , 2020, Journal of immunology research.

[30]  Zhiyi Liu,et al.  Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer , 2020, Cancer medicine.

[31]  D. Bartlett,et al.  In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2 , 2020, Molecular therapy oncolytics.

[32]  Zhihong Zhang,et al.  Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response , 2020, Nature Communications.

[33]  Honglin Luo,et al.  MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer , 2020, Molecular therapy oncolytics.

[34]  Zushun Xu,et al.  Co-Delivery of Bee Venom Melittin and a Photosensitizer with an Organic-Inorganic Hybrid Nanocarrier for Photodynamic Therapy and Immunotherapy. , 2019, ACS nano.

[35]  Honglin Luo,et al.  Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma , 2019, Molecular therapy oncolytics.

[36]  S. Rabkin,et al.  Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma , 2019, Oncoimmunology.

[37]  Zhihong Zhang,et al.  Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis , 2019, Nature Communications.

[38]  Y. Soda,et al.  Extremely Low Organ Toxicity and Strong Antitumor Activity of miR-34-Regulated Oncolytic Coxsackievirus B3 , 2019, Molecular therapy oncolytics.

[39]  Honglin Luo,et al.  Enteroviral Infection Leads to Transactive Response DNA-Binding Protein 43 Pathology in Vivo. , 2018, The American journal of pathology.

[40]  R. Heller,et al.  Nano‐pulse stimulation induces potent immune responses, eradicating local breast cancer while reducing distant metastases , 2018, International journal of cancer.

[41]  D. Bigner,et al.  Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs , 2017, Science Translational Medicine.

[42]  H. Mukhtar,et al.  Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. , 2017, Cancer letters.

[43]  C. Fillat,et al.  Implications of MicroRNAs in Oncolytic Virotherapy , 2017, Front. Oncol..

[44]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[45]  W. Gu,et al.  Triple-controlled oncolytic adenovirus expressing melittin to exert inhibitory efficacy on hepatocellular carcinoma. , 2015, International journal of clinical and experimental pathology.

[46]  Robert E W Hancock,et al.  Host defense peptides: front-line immunomodulators. , 2014, Trends in immunology.

[47]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[48]  A. Hemminki,et al.  An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  S. W. Kim,et al.  Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration. , 2011, Biomaterials.

[50]  I. Cuthill,et al.  Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .

[51]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..